Lipocalin-2, A-FABP and inflammatory markers in relation to flow-mediated vasodilatation in patients with essential hypertension

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Lipocalin families including lipocalin-2 and adipocyte fatty acid binding protein (A-FABP) were recently identified as novel adipokines to be associated with the cardiovascular risk variables of the metabolic syndrome. We evaluated the lipocalin-2 and A-FABP levels in 62 patients with essential hypertension (EHT) and 16 age-, gender-and body mass index-matched normotensive healthy subjects (NT). Furthermore, we evaluated the correlation between lipocalin-2, A-FABP levels, inflammatory markers including hsCRP and IL-10, and flow-mediated vasodilatation (FMD). In EHT, circulating lipocalin-2 levels were significantly higher than in NT (85.0o±o37.6ong/ml versus 43.8o±o13.1ong/ml, po<o0.001). However, A-FABP levels were not different between patients with EHT and NT. Serum lipocalin-2 levels were positively associated with SBP (ro=o0.54, po<o0.001), DBP (ro=o0.34, po=o0.003) and fasting glucose levels (ro=o0.25, po=o0.032), On the other hand, circulating A-FABP levels were significantly associated with variables such as BMI, fasting insulin, insulin resistance index and hsCRP. Multiple linear regression analysis showed that mean arterial pressure was associated with fasting glucose, lipocalin-2 levels, age, BMI and hsCRP levels (R2o=o0.456). However, circulating lipocalin-2 levels were not associated with FMD. In conclusion, lipocalin-2 levels were significantly higher in patients with EHT, and were independently associated with mean arterial pressure.

Original languageEnglish
Pages (from-to)478-483
Number of pages6
JournalClinical and Experimental Hypertension
Volume36
Issue number7
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Fatty Acid-Binding Proteins
Adipocytes
Vasodilation
Fasting
Arterial Pressure
Lipocalins
Glucose
Adipokines
Lipocalin-2
Essential Hypertension
Interleukin-10
Insulin Resistance
Linear Models
Healthy Volunteers
Body Mass Index
Regression Analysis
Insulin

Keywords

  • Adipocyte fatty acid binding protein
  • Adipokine
  • Hypertension
  • Lipocalin-2
  • Metabolic syndrome

ASJC Scopus subject areas

  • Internal Medicine
  • Physiology

Cite this

@article{930a22a2641e4c4ab1495ee87529b256,
title = "Lipocalin-2, A-FABP and inflammatory markers in relation to flow-mediated vasodilatation in patients with essential hypertension",
abstract = "Lipocalin families including lipocalin-2 and adipocyte fatty acid binding protein (A-FABP) were recently identified as novel adipokines to be associated with the cardiovascular risk variables of the metabolic syndrome. We evaluated the lipocalin-2 and A-FABP levels in 62 patients with essential hypertension (EHT) and 16 age-, gender-and body mass index-matched normotensive healthy subjects (NT). Furthermore, we evaluated the correlation between lipocalin-2, A-FABP levels, inflammatory markers including hsCRP and IL-10, and flow-mediated vasodilatation (FMD). In EHT, circulating lipocalin-2 levels were significantly higher than in NT (85.0o±o37.6ong/ml versus 43.8o±o13.1ong/ml, po2o=o0.456). However, circulating lipocalin-2 levels were not associated with FMD. In conclusion, lipocalin-2 levels were significantly higher in patients with EHT, and were independently associated with mean arterial pressure.",
keywords = "Adipocyte fatty acid binding protein, Adipokine, Hypertension, Lipocalin-2, Metabolic syndrome",
author = "Park, {Chang Gyu} and Choi, {Kyung Mook}",
year = "2014",
month = "1",
day = "1",
doi = "10.3109/10641963.2013.863320",
language = "English",
volume = "36",
pages = "478--483",
journal = "Clinical and Experimental Hypertension",
issn = "1064-1963",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Lipocalin-2, A-FABP and inflammatory markers in relation to flow-mediated vasodilatation in patients with essential hypertension

AU - Park, Chang Gyu

AU - Choi, Kyung Mook

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Lipocalin families including lipocalin-2 and adipocyte fatty acid binding protein (A-FABP) were recently identified as novel adipokines to be associated with the cardiovascular risk variables of the metabolic syndrome. We evaluated the lipocalin-2 and A-FABP levels in 62 patients with essential hypertension (EHT) and 16 age-, gender-and body mass index-matched normotensive healthy subjects (NT). Furthermore, we evaluated the correlation between lipocalin-2, A-FABP levels, inflammatory markers including hsCRP and IL-10, and flow-mediated vasodilatation (FMD). In EHT, circulating lipocalin-2 levels were significantly higher than in NT (85.0o±o37.6ong/ml versus 43.8o±o13.1ong/ml, po2o=o0.456). However, circulating lipocalin-2 levels were not associated with FMD. In conclusion, lipocalin-2 levels were significantly higher in patients with EHT, and were independently associated with mean arterial pressure.

AB - Lipocalin families including lipocalin-2 and adipocyte fatty acid binding protein (A-FABP) were recently identified as novel adipokines to be associated with the cardiovascular risk variables of the metabolic syndrome. We evaluated the lipocalin-2 and A-FABP levels in 62 patients with essential hypertension (EHT) and 16 age-, gender-and body mass index-matched normotensive healthy subjects (NT). Furthermore, we evaluated the correlation between lipocalin-2, A-FABP levels, inflammatory markers including hsCRP and IL-10, and flow-mediated vasodilatation (FMD). In EHT, circulating lipocalin-2 levels were significantly higher than in NT (85.0o±o37.6ong/ml versus 43.8o±o13.1ong/ml, po2o=o0.456). However, circulating lipocalin-2 levels were not associated with FMD. In conclusion, lipocalin-2 levels were significantly higher in patients with EHT, and were independently associated with mean arterial pressure.

KW - Adipocyte fatty acid binding protein

KW - Adipokine

KW - Hypertension

KW - Lipocalin-2

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84911908157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911908157&partnerID=8YFLogxK

U2 - 10.3109/10641963.2013.863320

DO - 10.3109/10641963.2013.863320

M3 - Article

C2 - 24491219

AN - SCOPUS:84911908157

VL - 36

SP - 478

EP - 483

JO - Clinical and Experimental Hypertension

JF - Clinical and Experimental Hypertension

SN - 1064-1963

IS - 7

ER -